Johnson & Johnson (JNJ) announced last night its decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as ...
The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...
Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...
This report covers significant developments in the health sector, including Johnson & Johnson halting a depression drug trial ...
Johnson & Johnson (NYSE:JNJ) has decided to discontinue a Phase 3 program for its depression therapy aticaprant due to insufficient efficacy, the pharma giant announced. Known as VENTURA ...
Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
6d
Zacks Investment Research on MSNJNJ Halts Development of Depression Drug Over Efficacy ConcernsJohnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an ...
J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.
From learning more about American rapper and songwriter Eve, to listening to the former First Lady of the United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results